Crossmark

Prognostic impact of combination therapy with gemcitabine and cisplatin plus S-1 and subsequent conversion surgery for initially unresectable upper biliary tract cancers

Crossref DOI link: https://doi.org/10.1007/s00595-024-02912-z

Published Online: 2024-08-13

Published Print: 2025-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kosaka, Hisashi

Matsui, Kosuke

Ikeura, Tsukasa

Ito, Takashi

Ohe, Chisato

Kono, Yumiko

Matsushima, Hideyuki

Yamamoto, Hidekazu

Sekimoto, Mitsugu

Kaibori, Masaki
License Information

Text and Data Mining valid from 2024-08-13

Version of Record valid from 2024-08-13
More Information

Article History

Received: 1 April 2024

Accepted: 2 July 2024

First Online: 13 August 2024

Declarations

:

: We have no conflicts of interest to declare.

: This study was approved by the institutional review board of Kansai Medical University (Approval number: 2021199). It was performed in accordance with the Declaration of Helsinki.

Document is current

Any future updates will be listed below